Related Experiment Video
Updated: Aug 7, 2026
14:25
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
SET complex in serous epithelial ovarian cancer
Véronique Ouellet1, Cécile Le Page, Marie-Claude Guyot
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM), Institut du cancer de Montréal, Montreal, Canada.
International Journal of Cancer
|July 11, 2006
Summary
Ovarian cancer is a chronic disease. SET complex protein expression correlates with tumor grade and stage, and specific combinations may predict patient prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ovarian cancer is increasingly viewed as a chronic illness due to low cure rates and varied treatment outcomes.
- Understanding factors driving ovarian cancer progression is crucial for managing this complex disease.
Purpose of the Study:
- To investigate the expression of SET complex proteins (SET, APE1, NM23, HMGB2, pp32) in serous epithelial ovarian tumors.
- To determine the correlation between SET complex protein expression, tumor grade, stage, and patient prognosis.
Main Methods:
- Immunohistochemistry was performed on a tissue array of 235 serous ovarian tumors.
- Analysis included assessment of tumor differentiation, disease stage, and patient survival data.
Main Results:
- SET complex protein expression significantly correlated with tumor differentiation (p < 0.05).
- Overexpression of Nm23, Set, and Ape1 was associated with advanced clinical stage.
- No single marker independently predicted prognosis, but combinations like high Nm23/low Set and high Hmgb2/low Ape1 showed prognostic significance.
Conclusions:
- SET complex protein expression is linked to ovarian tumor progression and clinical stage.
- Combinatorial analysis of SET complex protein expression may offer improved patient stratification and nomogram development for ovarian cancer.
